Zhouliang Wu

Zhouliang Wu

Auto-generated profile, based on publicly available information

Zhouliang Wu

Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Purpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma and muscle-invasive bladder cancer. This study evaluates the safety and efficacy of tislelizumab combined with low-dose nab-paclitaxel in extensive very high–risk non–muscle-invasive bladder cancer. Patients and Methods: TRUCE-02 was a single-arm phase II trial that included 63 patients with visually incomplete resection and/or high-volume high-grade T1 tumors (with or without carcinoma in situ) who were ineligible for or declined radical cystectomy. Patients received intravenous tislelizumab (200 mg on day 1) and nab-paclitaxel (200 mg on day 2) every 3 weeks, with assessment approximately 3 months after initial administration. The primary endpoint was the complete response (CR) rate of high-risk disease. Main secondary endpoints included safety and duration of CR. Results: The safety analysis included all 63 patients, and the efficacy analysis included 59 patients. Thirty-seven patients (62.7%; 95% confidence interval, 49.1%–75.0%) achieved a CR of high-risk disease, with a 24-month sustained response rate of 96.3% (95% confidence interval, 89.4%–100.0%). Grade 3 to 4 treatment-related adverse events occurred in nine patients (14%), with no fatal events reported. Conclusions: Tislelizumab plus low-dose nab-paclitaxel was well tolerated and showed promising antitumor activity, making it a potential alternative for patients with extensive very high–risk non–muscle-invasive bladder cancer who are ineligible for or decline radical cystectomy.

13 August 2024 in Nano Letters
Verified
Journal Article
Closed access
ZWZhouliang Wu
Zhouliang Wu
BLBozhao Li
Bozhao Li
YQYunkai Qie
Yunkai Qie
SWSuying Wu
Suying Wu
FQFeilong Qi
Feilong Qi
HHHailong Hu
Hailong Hu

24 December 2025 in Cancer Science
Verified
Journal Article
Open access
ZXZihan Xue
Zihan Xue
YQYunkai Qie
Yunkai Qie
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
HCHouyuan Chen
Houyuan Chen
HHHailong Hu
Hailong Hu
Repeat transurethral resection of bladder tumor (re‐TURBT) is commonly recommended for patients with non–muscle‐invasive bladder cancer (NMIBC) with high‐risk features, although many individuals may undergo unnecessary procedures that increase morbidity without clear benefit. Urinary tumor DNA (utDNA) has emerged as a promising biomarker, and we evaluated the performance of a multidimensional utDNA assay (utLIFE) in this context. In a retrospective cohort of 161 patients who underwent re‐TURBT between May 2020 and May 2025, urine samples collected 2–6 weeks after initial TURBT were analyzed using utLIFE, which integrates shallow whole‐genome sequencing and targeted sequencing of 155 genes with machine learning–based classification. Residual tumor was identified in 35% of patients, and utLIFE demonstrated high diagnostic accuracy, with sensitivity of 80.7%, specificity of 96.2%, and overall accuracy of 90.7%, markedly outperforming urine cytology. A positive utLIFE result was the strongest independent predictor of residual disease (OR = 77.5, 95% CI: 22.4–268.2, p < 0.001). During a median follow‐up of 32.5 months, recurrence occurred in 20.5% of patients; recurrence was defined as urothelial tumor relapse within the urinary tract and did not include distant metastasis. utLIFE positivity was significantly associated with shorter recurrence‐free survival (HR = 16.4, 95% CI: 2.7–101.8, p = 0.003). Longitudinal testing further revealed that utDNA positivity frequently preceded cystoscopic evidence of recurrence by several months. These findings highlight the strong diagnostic and prognostic value of utDNA in identifying residual disease and predicting recurrence, supporting its potential role in refining postoperative management strategies for NMIBC.

26 March 2026 in JCO Oncology Practice
Verified
Journal Article
Open access
ZXZihan Xue
Zihan Xue
YQYunkai Qie
Yunkai Qie
SLShan Liang
Shan Liang
RLRongjiang Li
Rongjiang Li
CSChong Shen
Chong Shen
HHHailong Hu
Hailong Hu
PURPOSE: The optimal adjuvant treatment approach for muscle-invasive bladder cancer (MIBC) remains unsettled. The IMvigor011 trial demonstrated that circulating tumor DNA (ctDNA)–guided adjuvant atezolizumab improves outcomes and advances precision oncology in this setting. However, the socioeconomic value of this biomarker-driven strategy is unclear. We therefore assessed the economic value of ctDNA-guided therapy in this postoperative setting. MATERIALS AND METHODS: We constructed a three-state Markov model to estimate costs, quality-adjusted life-years (QALYs), incremental net monetary benefit (INMB), and incremental cost-effectiveness ratios (ICERs) in patients with MIBC. The model compared a ctDNA-guided adjuvant atezolizumab strategy with the standard of care (SOC) from a US health care payer perspective. Cost-effectiveness was assessed across willingness-to-pay (WTP) thresholds of $50,000-$150,000 in US dollars (USD) per QALY, and model robustness was examined through comprehensive sensitivity analyses. RESULTS: Over a 5-year horizon, the ctDNA-guided strategy yielded 3.05 QALYs at a cost of $78,796 USD, compared with 2.92 QALYs and $131,601 USD for SOC. This corresponded to an ICER of –$397,163 USD per QALY gained, demonstrating dominance through greater benefit at lower cost. Sensitivity analyses confirmed that the ctDNA-guided approach was consistently cost-effective across all WTP thresholds. CONCLUSION: ctDNA-guided atezolizumab adjuvant therapy proves to be a cost-effective strategy for MIBC, optimizing health care resource allocation and reducing overtreatment while improving patient outcomes. More standardized ctDNA testing protocols and transparent reporting of ctDNA status distributions are essential.

3 March 2025
Verified
Other
Open access
PDF file
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Supplementary Table S5. Pathological staging at time of radical cystectomy.

3 March 2025
Verified
Other
Open access
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Supplementary Table S2. Complete response rate of any disease.